Rivaroxaban (BAY 59-7939)

This product is for research use only, not for human use. We do not sell to patients.

Rivaroxaban (BAY 59-7939)
For small sizes, please check our retail website as below: www.invivochem.com
Size Price Stock
2g$590Check With Us
5g$980Check With Us
10g$1470Check With Us

Cat #: V0948 CAS #: 366789-02-8 Purity ≥ 98%

Description: Rivaroxaban (BAY59-7939; BAY-59-7939; trade name: Xarelto), an approved anticoagulant drug used to treat and prevent blood clots, is the first orally bioavailable, selective and direct inhibitor of Factor Xa with potential anti-coagulant activity.

References: Roehrig S, et al. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J Med Chem. 2005 Sep 22;48(19)

Top Publications Citing Invivochem Products
Publications Citing InvivoChem Products

Product Promise

Promise
Molecular Weight (MW)435.88
Molecular FormulaC19H18ClN3O5S
CAS No.366789-02-8
Storage-20℃ for 3 years in powder formr
-80℃ for 2 years in solvent
Solubility In VitroDMSO: 87 mg/mL (199.6 mM)r
Water: <1 mg/mLr
Ethanol: <1 mg/mL
Solubility In Vivo0.5% methylcellulose+0.2% Tween 80: 5 mg/mL
SMILES CodeO=C(C1=CC=C(Cl)S1)NC[C@H]2CN(C3=CC=C(N4C(COCC4)=O)C=C3)C(O2)=O
SynonymsBAY 59-7939; Rivaroxaban; BAY59-7939; BAY-59-7939; trade name: Xarelto.
ProtocolIn VitroRivaroxaban (BAY 59-7939) is an oral, direct Factor Xa (FXa) inhibitor in development for the prevention and treatment of arterial and venous thrombosis. Rivaroxaban competitively inhibits human FXa (Ki 0.4 nM) with >10 000-fold greater selectivity than for other serine proteases; it also inhibits prothrombinase activity (IC50 2.1 nM). Rivaroxaban inhibits endogenous FXa more potently in human and rabbit plasma (IC50 21 nM) than rat plasma (IC50 290 nM). It demonstrates anticoagulant effects in human plasma, doubling prothrombin time (PT) and activates partial thromboplastin time at 0.23 and 0.69 μM, respectively.
In VivoRivaroxaban (BAY 59-7939) is a potent and selective, direct FXa inhibitor with excellent in vivo activity and good oral bioavailability.
These protocols are for reference only. InvivoChem does not independently validate these methods.
Preparing Stock Solutions
Solvent volume to be added Mass (the weight of a compound)
Mother liquor concentration 1mg5mg10mg20mg
1mM2.2942 mL11.4710 mL22.9421 mL45.8842 mL
5mM0.4588 mL2.2942 mL4.5884 mL9.1768 mL
10mM0.2294 mL1.1471 mL2.2942 mL4.5884 mL
20mM0.1147 mL0.5736 mL1.1471 mL2.2942 mL
Quality Control Documentation
The molarity calculator equation
Mass(g) = Concentration(mol/L) × Volume(L) × Molecular Weight(g/mol)
Mass
=
Concentration
×
Volume
×
Molecular Weight*
The dilution calculator equation
Concentration(start) × Volume(start) = Concentration(final) × Volume(final)

This equation is commonly abbreviated as: C1 V1 = C2 V2

Concentration(start)
C1
×
Volume(start)
V1
=
Concentration(final)
C2
×
Volume(final)
V2
Step One: Enter information below
Dosage mg/kg Average weight of animals g Dosing volume per animal µL Number of animals
Step Two: Enter the in vivo formulation
%DMSO + % + %Tween 80 + %ddH2O

Calculation Results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in µL DMSO(Master liquid concentration mg/mL) ,Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation: Take µL DMSO master liquid, next add µL PEG300, mix and clarify, next add µL Tween 80,mix and clarify, next add µL ddH2O,mix and clarify.
Note:
  • (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
  • (2) Be sure to add the solvent(s) in order.